Avery Dennison introduces sharp tear to help protect pharmaceutical brands from counterfeiting
LEIDEN, the Netherlands — October 10, 2012 — Avery Dennison has launched Sharp Tear™, an important new anti-counterfeiting technology that enables existing serial numbers to be read directly through the label, providing an extra layer of product security for pharmaceutical brands.
The innovative thin and clear co-extruded film is being introduced at a time when the pharmaceutical industry is facing new challenges brought on by the internet and the rapid globalization of the industry. Sharp Tear was designed for tamper-evident applications, where an easy tear is required in the label.
“The growth of internet sales, together with limited supplies of pharma products in some regions and significant price differentials, means that counterfeiting has become a very significant threat to all pharma brands,” said Hans Eichenwald, senior product manager Specialty Segments at Avery Dennison Materials Group. “Today, around 10% of drugs sold are already counterfeit according to the World Health Organization. Sharp Tear offers a rapid and reliable way to secure both product safety and brand reputation without impacting productivity or product margins.”
Sharp Tear is part of Avery Dennison’s comprehensive range of pharma anti-counterfeiting and anti-tampering products, which include security papers, films and voids.
The product reveals tampering immediately by providing a seal that remains intact during normal handling, but which tears easily in one direction if attempts are made to open the package.
Both exceptionally high clarity and very high opacity versions of Sharp Tear are available, allowing maximum flexibility across different packaging and product types. Sharp Tear can either mask unwanted packaging information or allow important product details to be visible through the label. The label material also delivers high mandrel performance with long term adhesion, and it comes with the regulatory compliance needed in pharma applications.
The innovative Sharp Tear material also improves productivity. A BG40 release liner allows conversion with conventional tooled dies, and the high adhesive coatweight guarantees a true tamper evident feature. It makes this product cost-efficient, delivering exceptional value for money in the pharma market.
Avery Dennison’s range of pharma anti-counterfeiting and anti-tampering products also includes customised UV-printed films and inserted UV threads, customised holograms and voids, and high-end taggents for ultimate security.
For more details of Sharp Tear and the wider Avery Dennison security range, go to www.europe.fasson.com.
About Avery Dennison
Avery Dennison (NYSE:AVY) is a global leader in labelling and packaging materials and solutions. The company’s applications and technologies are an integral part of products used in every major market and industry. With operations in more than 50 countries and 30,000 employees worldwide, Avery Dennison serves customers with insights and innovations that help make brands more inspiring and the world more intelligent. Headquartered in Pasadena, California, the company reported sales from continuing operations of $6 billion in 2011. Learn more at www.averydennison.com.
For more information:
Avery Dennison EMG
Rob Verbruggen Ankiza Gakunu
T: +31 (0) 71 579 4232 T: +31 164 317 025
This press release can be downloaded from www.PressReleaseFinder.com